SLDB's Business Model
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.solidbio.com |
| CEO (Chief Executive Officer) | Alexander G. Cumbo |
| Number of Employees | |
| IPO date | January 26, 2018 |
SLDB Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 141 Portland Street |
| City | Cambridge |
| State | MA |
| Phone | 617 337 4680 |
| Zip Code | 02139 |
| Other Identifiers | |
| CIK | 0001707502 |
| ISIN | US83422E2046 |
| CUSIP | 83422E105 |
| Open | 7.46 |
| Previous Close | 7.48 |
| Volume | 1.62 Mil. |
| Average Volume | 1.34 Mil. |
| Day’s Range | 7.34 – 7.99 |
| 52 Week Range | 2.41-8.72 |
| MA (50) | 6.3129 |
| MA (200) | 5.6789 |
| Market Cap | 604.6 Mil. |
| Shares Out. | 77.91 Mil. |
| Earnings Date | Mar 24, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
